Researchers say the discovery is significant because current sleep-facilitating drugs typically only increase the duration of non-REM sleep.
Summary: Researchers have identified melatonin as a crucial regulator of REM sleep and discovered that the melatonin MT1 receptor can be selectively targeted to enhance REM sleep without affecting non-REM sleep. Researchers say this discovery could lead to the development of new therapies for conditions associated with REM sleep dysfunction, such as Parkinson’s disease and Lewy body dementia. They note the findings are significant because current sleep medications generally only increase non-REM sleep duration, leaving REM sleep largely unaffected.
Three Key Takeaways:
- Selective REM Sleep Enhancement: Researchers have discovered that melatonin, through its MT1 receptor, can selectively enhance REM sleep without altering non-REM sleep, a discovery they say could lead to more targeted sleep therapies.
- Therapeutic Potential: The identification of the MT1 receptor as a key regulator of REM sleep provides a new target for developing treatments for serious disorders like Parkinson’s disease and Lewy body dementia, which are associated with REM sleep dysfunction.
- Significance for Current Sleep Medications: Researchers say the discovery is important because current sleep drugs typically only increase non-REM sleep, and this new approach could address the gap in treatments that specifically target REM sleep.
Researchers have pinpointed melatonin as a crucial regulator of REM sleep and discovered the first molecule capable of selectively acting on REM sleep without altering non-REM sleep.
The research, published in the Journal of Neuroscience, was conducted by a team of scientists led by Gabriella Gobbi, MD, PhD, at the Research Institute of the McGill University Health Centre and Stefano Comai, PhD, at the University of Padua.
Human sleep unfolds in a precise sequence of non-REM (rapid eye movement) and REM stages, each serving distinct physiological functions. REM sleep plays a pivotal role in memory consolidation and emotional regulation, while non-REM sleep supports physical recovery and repair processes.
Disruptions in this cycle can impair cognitive function and increase vulnerability to neuropsychiatric diseases.
The researchers say their discovery provides a target for the development of new therapies for serious disorders associated with REM sleep dysfunction, such as Parkinson’s disease and Lewy body dementia—which currently lack effective treatments.
The Sleep Hormone
Also known as the sleep hormone, melatonin is a molecule secreted by the pineal gland in the brain. It facilitates sleep by acting on receptors involved in the regulation of circadian rhythms and sleep, named MT1 and MT2. However, until now, the specific receptor triggering REM sleep had eluded scientists. The new study has identified the melatonin MT1 receptor as an important regulator of this sleep stage.
“This discovery not only advances our understanding of sleep mechanisms but also holds significant clinical potential,” says Gobbi, co-senior author of the study, senior scientist in the Brain Repair and Integrative Neuroscience (BRaIN) Program at the Research Institute of the McGill University Health Centre, professor of psychiatry at McGill University, and Canada Research Chair in Therapeutics for Mental Health, in a release.
The Science of Snoozing
In the brain, melatonin’s MT1 receptor interacts with a type of neuron called noradrenaline (or norepinephrine) found in an area known as the locus coeruleus, or “blue spot” in Latin. During REM sleep, these neurons quiet down and stop their activity.
Using a novel drug that activates MT1 receptors, researchers were able to reduce the activity of these neurons in experimental animals, with the effect of successfully increasing the duration of REM sleep. This is significant because current sleep-facilitating drugs typically only increase the duration of non-REM sleep.
“Currently, there are no drugs specifically targeting REM sleep. Most hypnotic drugs on the market, while extending total sleep duration, tend to adversely affect REM sleep,” says Comai, co-senior author of the study, professor at the University of Padua, and adjunct professor at McGill University, in a release.
Approximately 0.5-1% of the general population is affected by REM sleep behavior disorder, which is a serious risk factor for the development of certain neurodegenerative diseases.
Further research into the neurobiology and pharmacology of REM sleep is crucial for developing targeted treatments that could improve the quality of life for patients affected by these debilitating diseases, according to the researchers. As scientists continue to explore the complexities of sleep regulation, the hope for effective interventions in neurological disorders grows increasingly promising.
